Shorla Oncology, are delighted to announce the appointment of Dennis Purcell as Board Chairman. As a pre-eminent leader in the biotech industry, Purcell brings significant experience that will help guide Shorla in bringing their novel oncology products to the U.S. market.
Purcell is the original Founder of Aisling Capital LLC, a leading life sciences investment firm based in New York City with $1.8 billion in committed capital and a track record of investing and returning capital since 2000. Prior to Aisling Capital, Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”). Purcell has also served as Director on a number of biotechnology company boards including Aton Pharma (acquired by Merck), Bridge Pharmaceuticals (acquired by Pharmaron), Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals.
Read more at: https://www.businesswire.com/news/home/20220329005173/en/Shorla-Oncology-Appoints-Dennis-Purcell-as-Chairman-of-the-Board-of-Directors
